Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$542.15 +0.8%	$585.62	$428.76 ▼ $678.21	$33.10B	0.39	324,461 shs	372,905 shs
BNTX BioNTech	$106.53 +2.0%	$102.22	$76.53 ▼ $131.49	$25.61B	1.29	946,428 shs	721,507 shs
GMAB Genmab A/S	$21.16 -1.9%	$20.89	$17.24 ▼ $28.56	$13.57B	0.96	1.18 million shs	1.75 million shs
TAK Takeda Pharmaceutical	$14.75 -1.0%	$14.79	$12.78 ▼ $15.43	$46.92B	0.23	1.95 million shs	3.41 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	-6.18%	-7.74%	-10.82%	+37.44%
BNTX BioNTech	0.00%	-0.04%	+7.96%	+5.85%	+25.86%
GMAB Genmab A/S	0.00%	-7.27%	+1.68%	+9.69%	-18.71%
TAK Takeda Pharmaceutical	0.00%	-2.99%	+1.17%	-1.80%	+17.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	4.3675 of 5 stars	4.5	4.0	0.0	2.5	1.7	2.5
BNTX BioNTech	2.4629 of 5 stars	4.4	3.0	0.0	1.0	0.8	0.0
GMAB Genmab A/S	3.7565 of 5 stars	3.3	5.0	0.0	2.0	0.0	3.1
TAK Takeda Pharmaceutical	0.8409 of 5 stars	0.0	3.0	1.7	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.05	Buy	$709.18	30.81% Upside
BNTX BioNTech	2.83	Moderate Buy	$137.86	29.41% Upside
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	85.10% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest GMAB, TAK, ARGX, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/11/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/10/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/2/2025	BNTX BioNTech	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$112.00
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/21/2025	ARGX argenex	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $134.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	14.70	$2.97 per share	182.51	$90.49 per share	5.99
BNTX BioNTech	$2.98B	8.60	N/A	N/A	$87.61 per share	1.22
GMAB Genmab A/S	$3.12B	4.35	$1.52 per share	13.95	$8.04 per share	2.63
TAK Takeda Pharmaceutical	$30.09B	1.56	$3.18 per share	4.64	$14.39 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	33.45	49.97	0.98	40.20%	16.15%	14.33%	7/24/2025 (Estimated)
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.76	12.02	11.89	6.98	35.11%	18.08%	14.52%	8/14/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	67.03	8.94	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest GMAB, TAK, ARGX, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.27	1.83%	N/A	122.73%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
BNTX BioNTech	0.01	10.18	10.02
GMAB Genmab A/S	N/A	5.34	5.32
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BNTX BioNTech	15.52%
GMAB Genmab A/S	7.07%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BNTX BioNTech	19.20%
GMAB Genmab A/S	1.54%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.06 million	59.58 million	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
GMAB Genmab A/S	2,682	641.22 million	631.35 million	Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable

GMAB, TAK, ARGX, and BNTX Headlines

Recent News About These Companies

Yousif Capital Management LLC Has $444,000 Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK)

June 21 at 3:27 AM | marketbeat.com

Inscription Capital LLC Invests $303,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

June 19, 2025 | marketbeat.com

Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

June 18, 2025 | kxan.com

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Purchased by QRG Capital Management Inc.

June 18, 2025 | marketbeat.com

Trump rekindles pharmaceutical tariff threat, suggesting import duties could come 'very soon': Reuters

June 17, 2025 | fiercepharma.com

Class Status Upheld in Takeda, Eli Lilly RICO Suit Over Actos

June 17, 2025 | news.bloomberglaw.com

GAMMA Investing LLC Has $1.56 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 15, 2025 | marketbeat.com

Sun Pharma announce major leadership shake-up, names Kirti Ganorkar as MD, Shanghvi steps into executive Chairman Role

June 14, 2025 | moneycontrol.com

Sun Pharma names Kirti Ganorkar as new managing director, Dilip Shanghvi to continue as chairman

June 13, 2025 | msn.com

Wealth Enhancement Advisory Services LLC Lowers Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 9, 2025 | marketbeat.com

Clean Yield Group Lowers Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 8, 2025 | marketbeat.com

Takeda CEO Christophe Weber faces opposition to board reelection

June 7, 2025 | asia.nikkei.com

Itochu working to support overseas pharma firms to fill Japan's drug gaps

June 4, 2025 | japantimes.co.jp

Takeda Reports Adcetris Combo Approved by EC for Hodgkin Lymphoma

June 4, 2025 | msn.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by NBC Securities Inc.

June 4, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Up 33.3% in May

June 3, 2025 | marketbeat.com

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection

June 3, 2025 | business-standard.com

Rusfertide reduces blood draws, maintains hematocrit, eases symptoms in polycythemia vera

June 2, 2025 | healio.com

ASCO: Takeda and Protagonist release positive Phase III VERIFY study of rusfertide in polycythemia vera

June 2, 2025 | thepharmaletter.com

Legacy Wealth Asset Management LLC Buys 44,635 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 2, 2025 | marketbeat.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 1, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Applied Digital: Now the High-Stakes Race to Build Begins
By Jeffrey Neal Johnson | June 17, 2025
View Applied Digital: Now the High-Stakes Race to Build Begins
Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
By Leo Miller | June 10, 2025
View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names
Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?
By Nathan Reiff | June 20, 2025
View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?

GMAB, TAK, ARGX, and BNTX Company Descriptions

argenex NASDAQ:ARGX

$542.15 +4.23 (+0.79%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$542.57 +0.42 (+0.08%)

As of 06/20/2025 06:15 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$106.53 +2.13 (+2.04%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$105.60 -0.93 (-0.87%)

As of 06/20/2025 07:22 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Genmab A/S NASDAQ:GMAB

$21.16 -0.40 (-1.86%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$21.60 +0.44 (+2.06%)

As of 06/20/2025 06:49 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Takeda Pharmaceutical NYSE:TAK

$14.74 -0.16 (-1.04%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$15.13 +0.39 (+2.64%)

As of 06/20/2025 06:57 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time